Intelligence Feed event · Policy · 2026-10-01

    Theriva Biologics VIRAGE Trial in Pancreatic Cancer Published in Nature Medicine

    Question

    Theriva Biologics VIRAGE Trial in Pancreatic Cancer Published in Nature Medicine

    Direct answer

    Theriva Biologics announced the peer-reviewed publication of its Phase 2b VIRAGE trial results in Nature Medicine. The trial assessed VCN-01 combined with standard chemotherapy in metastatic pancreatic cancer, demonstrating gains across overall survival, progression-free survival, and response duration.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Theriva Biologics VIRAGE Trial in Pancreatic Cancer Published in Nature Medicine”, revision 1, evidence through 2026-10-01. https://marketontology.com/market-events/2026-10-01/theriva-biologics-virage-trial-in-pancreatic-cancer-published-in-nature-medicine-0053b2

    POLICY
    Theriva Biologics VIRAGE Trial in Pancreatic Cancer Published in Nature Medicine
    Theriva Biologics announced the peer-reviewed publication of its Phase 2b VIRAGE trial results in Nature Medicine. The trial assessed VCN-01 combined with standard chemotherapy in metastatic pancreatic cancer, demonstrating gains across overall survival, progression-free survival, and response duration.
    TOVX
    Impact
    65
    OCT 1
    SIG
    85%
    TOVX
    Theriva Biologics VIRAGE Trial in Pancreatic Cancer Published in Nature Medicine
    Theriva Biologics announced the peer-reviewed publication of its Phase 2b VIRAGE trial results in Nature Medicine. The trial assessed VCN-01 combined with standard chemotherapy in metastatic pancreatic cancer, demonstrating gains across overall survival, progression-free survival, and response duration.
    → Peer-reviewed Phase 2b clinical survival data for VCN-01 in Nature Medicine accelerates potential partnership and regulatory milestones for TOVX.
    Impact
    Theriva Biologics announced the peer-reviewed publication of its Phase 2b VIRAGE trial results in Nature Medicine. The trial assessed VCN-01 combined with standard chemotherapy in metastatic pancreatic cancer, demonstrating gains across overall survival, progression-free survival, and response duration.
    Affected
    TOVX
    Transmission
    Peer-reviewed Phase 2b clinical survival data for VCN-01 in Nature Medicine accelerates potential partnership and regulatory milestones for TOVX.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    TOVXbiotech clinical pipeline valuation repricing on positive trial publicationUp1-5dNature Medicine published Phase 2b VIRAGE trial results showing improved survival metrics.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month